A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma

BACKGROUND: Preclinical studies suggest that BRAF inhibitors enhance anti-tumor immunity and antigen presentation. Combination BRAF inhibition with immunotherapy is an appealing therapeutic approach. We sequenced vemurafenib with HD IL-2 in patients with BRAF-mutated metastatic melanoma to improve l...

Descripción completa

Detalles Bibliográficos
Autores principales: Clark, Joseph I., Singh, Jatinder, Ernstoff, Marc S., Lao, Christopher D., Flaherty, Lawrence E., Logan, Theodore F., Curti, Brendan, Agarwala, Sanjiv S., Taback, Bret, Cranmer, Lee, Lutzky, Jose, Luna, Theresa L., Aung, Sandra, Lawson, David H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6062934/
https://www.ncbi.nlm.nih.gov/pubmed/30053905
http://dx.doi.org/10.1186/s40425-018-0387-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6062934/
https://www.ncbi.nlm.nih.gov/pubmed/30053905
http://dx.doi.org/10.1186/s40425-018-0387-x

Ejemplares similares